Short communication: Oral lesions in HIV/AIDS patients undergoing HAART including efavirenz

AIDS Research and Human Retroviruses

Volumn 24, Issue 6, 2008, Pages 815-820

  Aquino Garcia S I ^a   Rivas, M A ^b   Ceballos Salobrena A ^c   Acosta Gio, A E ^a   Gaitan Cepeda L A ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; AIDS PATIENT; ARTICLE; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CHI SQUARE TEST; CONTROLLED STUDY; FEMALE; GENDER; HERPES LABIALIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEXICO; MOUTH EXAMINATION; MOUTH LESION; PERIODONTITIS; PREVALENCE; PRIORITY JOURNAL; SOFT TISSUE; TREATMENT DURATION; VIRUS LOAD; XEROSTOMIA;

EID: 45749083434     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0159     Document Type: Article

References (41)

1. Schmit JC and Weber B: Recent advances in antiretroviral therapy and HIV infection monitoring. Intervirology 1997;40:304-321.
2. Ibanez A, Puig T, Elias J, Clotet B, Ruiz L, and Martinez MA: Quantification of integrated and total HIV-1 DNA after longterm highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999;13:1045-1049.
3. de la Rosa R, Ruiz-Mateos E, Rubio A, et al.: Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. J Antimicrob Chemother 2004;53:95-101.
4. Lederman MM, Connick E, Landay A, et al.: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-79.
5. Jansen CA, Piriou E, De Cuyper IM, et al.: Long-term highly active antiretroviral therapy in chronic HIV-1 infection: Evidence for reconstitution of antiviral immunity. Antiviral Ther 2006;11:105-116.
6. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
7. Michelet C, Arvieux C, Francois C, et al.: Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998;12:1815-1822.
8. Aguirre-Urizar JM, Echebarría-Goicouría MA, and Eguía-Del Valle A: Acquired immunodeficiency syndrome: Manifestations in the oral cavity. Med Oral Pathol Oral Cir Bucal 2004(9 Suppl.):S148-157.
9. Greenspan D, Gange SJ, Phelan JA, et al.: Incidence of oral lesions in HIV-1-infected women: Reduction with HAART. J Dent Res 2004;83:145-150.
10. Ceballos-Salobreña A, Gaitan-Cepeda LA, Ceballos-Garcia L, and Lezama-Del Valle D: Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: A new face of oral AIDS? AIDS Patient Care STDS 2000;14:627-635.
11. Schmidt-Westhausen A, Priepke F, Bergman F, and Reichart PA: Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 2000;29:336-341.
12. Porter S and Scully C: HIV topic update: Protease inhibitor therapy and oral health care. Oral Dis 1998;4:159-163.
13. Chen LF, Hoy J, and Lewin SR: Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007;186:146-151.
14. Hofman P and Nelson AM: The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: An update. Curr Med Chem 2006;13:3121-3132.
15. Garcia R, Badaro R, Netto EM, et al.: Cross-sectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian HIV-infected patients. AIDS Res Hum Retroviruses 2006;22:1248-1252.
16. Barrios A, Negredo E, Domingo P, et al.: Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial. Antiviral Ther 2005;10:825-832.
17. Santos J, Palacios R, Lopez M, et al.: Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naive patients: The VESD study. HIV Clin Trials 2005;6:320-328.
18. Perez-Elias MJ, Moreno A, Moreno S, et al.: Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. HIV Clin Trials 2005;6:312-319.
19. Panel de expertos de GESIDA; Plan Nacional sobre el Sida: Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007). Enferm Infecc Microbiol Clin 2007;25:32-53.
20. Sax PE: Updated DHHS treatment guidelines. AIDS Clin Care 2006;18:105.
21. Birnbaum W, Hodgson TA, Reichart PA, Sherson W, Nittayannata SW, and Axell TE: Prognostic significance of HIV-associated oral lesions and their relation to therapy. Oral Dis 2002;8:110-114.
22. Gaitán-Cepeda L, Martínez-González M, and Ceballos-Salobreña A: Oral candidiosis as clinical marker of immune failure in HIV /AIDS patients undergoing highly active antiretroviral therapy. AIDS Patients Care STDS 2005;19:70-77.
23. EC-Clearinghouse on Oral Problems Related to HIV infection and WHO Collaborating Centre on Oral Manifestations of the immunodeficiency Virus: Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1992;22:289-291.
24. Reznik DA: Perspective - oral manifestations of HIV disease. Top HIV Med 2005;13:143-148.
25. Robinson PG: Which periodontal changes are associated with HIV infection? J Clin Periodontol 1998;25:278-285.
26. Coogan M, Greenspan J, and Challacombe S: Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ 2005;83:700-706.
27. Barone R, Ficarra G, Gaglioti D, Orsi A, and Mazzotta F: Prevalence of oral lesions among HIV-infected intravenous drug abuser and other risk groups. Oral Surg Oral Med Oral Pathol 1990;69:169-173.
28. Chattopadhyay A, Capalan DJ, Slade GD, Shugars DC, Tien H-C, and Patton LL: Risk indicator for oral candidiasis and oral hairy leukoplakia in HIV-infected adults. Community Den Oral Epidemiol 2005;33:34-35.
29. Campo J, Del Romero J, Castilla J, García S, Rodríguez C, and Bascones A: Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med 2002;31:5-10.
30. Ceballos A, Aguirre JM, and Bagán JV: Oral manifestations associated with human immunodeficiency virus infection in a Spanish population. J Oral Pathol Med 1996;25:523-536.
31. Moniaci D, Greco D, Flecchia G, Raiteri R, and Sinicco AI: Epidemiology, clinical features and prognostic value of HIV-1 related oral lesions. J Oral Pathol Med 1990;19:477-481.
32. Tukutuku K, Muyembe-Tamfum L, Kayembe K, Mavuemba T, Sangra N, and Sekele I: Prevalence of dental caries, gingivitis and oral hygiene in hospitalized AIDS cases in Kinshasa, Zaire. J Oral Pathol Med 1990;19:271-272.
33. Ramírez-Amador VA, Esquivel-Pedraza L, Ponce-de-León S, and Ponce-de-León S: Prognostic value of oral candidosis and hairy leukoplakia in 111 Mexican HIV-infected patients. J Oral Pathol Med 1996;25:206-211.
34. Naglik JR, Challacombe SJ, and Hube B: Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003;67:400-428.
35. Asencio MA, Garduno E, Perez-Giraldo C, Blanco MT, Hurtado C, and Gomez-Garcia AC: Exposure to therapeutic concentrations of ritonavir, but not saquinavir, reduces secreted aspartyl proteinase of Candida parapsilosis. Chemotherapy 2005;51:252-255.
36. Backman D, Monod M, and Danielson UH: Biosensor-based screening and characterization of HIV-1 inhibitor interactions with Sap 1, Sap 2, and Sap 3 from Candida albicans. J Biomol Screen 2006;11:165-175.
37. Cassone A, Tacconelli E, De Bernardis F, et al.: Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis 2002;185:188-195.
38. Migliorati CA, Birman EG, and Cury AE: Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:301-310.
39. De Bernardis F, Tacconelli E, Mondello F, et al.: Antiretroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their antimycotic susceptibility. FEMS Immunol Med Microbiol 2004;41:27-34.
40. Falkensammer B, Pilz G, Bektic L, et al.: Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells. Mycoses 2007;50:172-177.
41. Gruber A, Berlit J, Speth C, et al.: Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors. Immunobiology 1999;201:133-144.